{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:58:37Z","timestamp":1783702717666,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clinthera.2025.01.013","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T13:35:54Z","timestamp":1741268154000},"page":"377-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Effect of Ulinastatin on Sepsis Outcomes: An Umbrella Review of Meta-Analysis"],"prefix":"10.1016","volume":"47","author":[{"given":"Sheng","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.01.013_bib0001","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0002","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40273-015-0282-y","article-title":"The economic and humanistic burden of severe sepsis","volume":"33","author":"Tiru","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0003","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1164\/rccm.201504-0781OC","article-title":"Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations","volume":"193","author":"Fleischmann","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0004","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.suc.2017.07.003","article-title":"Sepsis and septic shock strategies","volume":"97","author":"Armstrong","year":"2017","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0005","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0006","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00281-017-0639-8","article-title":"Cytokine storm and sepsis disease pathogenesis","volume":"39","author":"Chousterman","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0007","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.immuni.2021.10.012","article-title":"The immunology of sepsis","volume":"54","author":"van der Poll","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0008","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00134-019-05908-3","article-title":"Rate and risk factors for rehospitalisation in sepsis survivors: systematic review and meta-analysis","volume":"46","author":"Shankar-Hari","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0009","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0010","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","article-title":"Time to treatment and mortality during mandated emergency care for sepsis","volume":"376","author":"Seymour","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0011","first-page":"488","article-title":"Action of antiproteases on the inflammatory response in acute pancreatitis","volume":"8","author":"Chen","year":"2007","journal-title":"JOP"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0012","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s00134-014-3366-9","article-title":"An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitor","volume":"40","author":"Linder","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0013","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.bbrc.2016.04.104","article-title":"Ulinastatin attenuates LPS-induced human endothelial cells oxidative damage through suppressing JNK\/c-Jun signaling pathway","volume":"474","author":"Li","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0014","first-page":"s109","article-title":"Ulinastatin, a protease inhibitor, may inhibit allogeneic blood transfusion-associated pro-inflammatory cytokines and systemic inflammatory response syndrome and improve postoperative recovery","volume":"12","author":"Shu","year":"2014","journal-title":"Blood Transfus"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0015","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.21037\/jtd.2019.05.03","article-title":"Use of ulinastatin was associated with reduced mortality in critically ill patients with sepsis","volume":"11","author":"Xu","year":"2019","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0016","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/0885066608326970","article-title":"A new immunomodulatory therapy for severe sepsis: ulinastatin plus Thymosin {alpha} 1","volume":"24","author":"Li","year":"2009","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0017","first-page":"147","article-title":"[Clinical effects of ulinastatin and thymosin alpha1 on immune-modulation in septic patients]","volume":"21","author":"Su","year":"2009","journal-title":"Zhongguo Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0018","first-page":"269","article-title":"The clinical study of ulinastatin and Xuebijing on elderly patients with severe pneumonia","volume":"19","author":"Chen","year":"2014","journal-title":"J Lingnan Emerg Med"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.899753","article-title":"Efficacy of Xuebijing combined with Ulinastatin in the treatment of traumatic sepsis and effects on inflammatory factors and immune function in patients","volume":"9","author":"Su","year":"2022","journal-title":"Front Surg"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0020","article-title":"Efficacy and safety of Xuebijing injection combined with ulinastatin as adjunctive therapy on sepsis: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0021","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/TA.0000000000000909","article-title":"Ulinastatin and\/or thymosin \u03b11 for severe sepsis: a systematic review and meta-analysis","volume":"80","author":"Feng","year":"2016","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0022","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ajem.2017.12.007","article-title":"Xuebijing combined with ulinastatin benefits patients with sepsis: a meta-analysis","volume":"36","author":"Zheng","year":"2018","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0023","doi-asserted-by":"crossref","first-page":"e31196","DOI":"10.1097\/MD.0000000000031196","article-title":"The effects of Xuebijing injection combined with ulinastatin as adjunctive therapy on sepsis: an overview of systematic review and meta-analysis","volume":"101","author":"Zhong","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0024","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0025","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ajem.2017.12.007","article-title":"Xuebijing combined with ulinastatin benefits patients with sepsis: a meta-analysis","volume":"36","author":"Zheng","year":"2018","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0026","first-page":"e10971","article-title":"Curative efficacy and safety of traditional Chinese medicine Xuebijing injections combined with ulinastatin for treating sepsis in the Chinese population: a meta-analysis","volume":"97","author":"Xiao","year":"2018","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0027","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3389\/fphar.2019.01370","article-title":"Improvement of sepsis prognosis by ulinastatin: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Wang","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0028","doi-asserted-by":"crossref","first-page":"A807","DOI":"10.1016\/j.jval.2014.08.528","article-title":"Meta-analysis of Xuebijing joint ulinastatin treating sepsis","volume":"17","author":"Liu","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0029","article-title":"Traditional Chinese medicine for septic patients undergoing ulinastatin therapy A meta-analysis","volume":"100","author":"Shan","year":"2021","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0030","article-title":"The efficacy and immunomodulatory effects of ulinastatin and thymosin \u03b1 1 for sepsis: a systematic review and meta-analysis","volume":"2016","author":"Wang","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0031","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.intimp.2015.10.026","article-title":"Ulinastatin- and thymosin \u03b11-based immunomodulatory strategy for sepsis: a meta-analysis","volume":"29","author":"Han","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0032","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3389\/fphar.2018.00743","article-title":"Efficacy and safety of Xuebijing injection combined with ulinastatin as adjunctive therapy on sepsis: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0033","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3389\/fphar.2018.00743","article-title":"Efficacy and safety of Xuebijing Injection combined with Ulinastatin as adjunctive therapy on sepsis: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0034","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jcrc.2017.02.005","article-title":"Effect of ulinastatin combined with thymosin alpha1 on sepsis: a systematic review and meta-analysis of Chinese and Indian patients","volume":"39","author":"Liu","year":"2017","journal-title":"J Crit Care"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0035","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3389\/fphar.2019.01370","article-title":"Improvement of sepsis prognosis by Ulinastatin: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Wang","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0036","doi-asserted-by":"crossref","first-page":"e10971","DOI":"10.1097\/MD.0000000000010971","article-title":"Curative efficacy and safety of traditional Chinese medicine Xuebijing injections combined with ulinastatin for treating sepsis in the Chinese population: a meta-analysis","volume":"97","author":"Xiao","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0037","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ajem.2017.12.007","article-title":"Xuebijing combined with ulinastatin benefits patients with sepsis: a meta-analysis","volume":"36","author":"Zheng","year":"2018","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0038","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/TA.0000000000000909","article-title":"Ulinastatin and\/or thymosin \u03b11 for severe sepsis: a systematic review and meta-analysis","volume":"80","author":"Feng","year":"2016","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12890-019-0968-6","article-title":"Ulinastatin treatment for acute respiratory distress syndrome in China: a meta-analysis of randomized controlled trials","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01370","article-title":"Improvement of sepsis prognosis by ulinastatin: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Wang","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0041","doi-asserted-by":"crossref","first-page":"5558687","DOI":"10.1155\/2021\/5558687","article-title":"Ulinastatin ameliorates IL-1\u03b2-induced cell dysfunction in human nucleus pulposus cells via Nrf2\/NF-\u03bab pathway","volume":"2021","author":"Luo","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12950-017-0154-7","article-title":"Ulinastatin ameliorates tissue damage of severe acute pancreatitis through modulating regulatory T cells","volume":"14","author":"Pan","year":"2017","journal-title":"J Inflamm"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0043","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/geriatrics9020045","article-title":"Inflammaging in multidrug-resistant sepsis of geriatric ICU patients and healthcare challenges","volume":"9","author":"Kumar","year":"2024","journal-title":"Geriatrics"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0044","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/pathogens13020164","article-title":"The role of the nuclear factor-kappa B (NF-\u03baB) pathway in SARS-CoV-2 infection","volume":"13","author":"Kesika","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0045","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1089\/sur.2019.363","article-title":"Staging and personalized intervention for infection and sepsis","volume":"21","author":"Beckmann","year":"2020","journal-title":"Surg Infect"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1296061","article-title":"Bacteria-derived extracellular vesicles: endogenous roles, therapeutic potentials and their biomimetics for the treatment and prevention of sepsis","volume":"15","author":"Effah","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116300","article-title":"Advances in molecular agents targeting toll-like receptor 4 signaling pathways for potential treatment of sepsis","volume":"268","author":"Zheng","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0048","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1515\/jbcpp-2015-0003","article-title":"Ulinastatin\u2014a newer potential therapeutic option for multiple organ dysfunction syndrome","volume":"27","author":"Atal","year":"2016","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0049","article-title":"Pharmacological interventions for acute pancreatitis","volume":"4","author":"Moggia","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0050","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.intimp.2013.09.004","article-title":"Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model","volume":"17","author":"Wang","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0051","series-title":"Nijkamp and Parnham's Principles of Immunopharmacology","first-page":"533","article-title":"Immunomodulation in sepsis and infection","author":"Giamarellos-Bourboulis","year":"2019"},{"key":"10.1016\/j.clinthera.2025.01.013_bib0052","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.bbrc.2016.04.104","article-title":"Ulinastatin attenuates LPS-induced human endothelial cells oxidative damage through suppressing JNK\/c-Jun signaling pathway","volume":"474","author":"Li","year":"2016","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:35:02Z","timestamp":1744202102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0149291825000141"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Ulinastatin on Sepsis Outcomes: An Umbrella Review of Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}